Abstract: Exemplary systems, methods, and computer-accessible mediums can be provided that can generate resultant data regarding fiber tract(s) and anatomical structure(s). For example, first information related to imaging data of the anatomical structure(s) can be received. Second information related to a predictive model of further fiber tract(s) can be received. The resultant data can be generated based on the first information, the second information and a fiber cost procedure.

Abstract: The present invention relates to a method for identifying inhibitors of breast cancer metastasis based on a screening with proteins that are specific for the secretome of a chondrocyte, preferably cytokines and/or chemokines. The ligands as identified lead to a decrease of the migration and/or a re-differentiation of a breast cancer cell and/or a reduction of the number and/or size of breast cancer metastases. The present invention further relates to a method for detecting breast cancer metastasis, comprising the step of detecting at least one protein that is specific for the secretome of a chondrocyte, and for methods for treating and/or preventing breast cancer metastasis in a patient in need thereof, comprising the step of administering an effective amount of at least one ligand for one protein that is specific for the secretome of a chondrocyte to said patient in need thereof.

Abstract: The present invention relates to an in vitro process for the diagnosis of prostate cancer and other tumor types in exosomes obtained from a body fluid which comprises a) concentrating the exosomes and other extracellular vesicles from a body fluid of a patient, b) extraction of total RNA from the exosomes obtained in step a), c) conversion of the RNA obtained in step b) to cDNA, d) amplification of the cDNA obtained in step c) with a polymerase chain reaction whereby primers derived from the AGR2 nucleotide sequence or the complement thereof are used, and e) determining whether in the amplification product variants of the AGR2 gene can be identified.

Abstract: A method and a system for calibrating a network of multiple range finders are disclosed. In an embodiment, the method includes performing a measurement with the range finders during a movement of an object through an area covered by the network, identifying, for each range finder, data sets of the measurement associated with the moving object, based on a static analysis of the respective range finder, determining, for each pair of overlapping range finders, an estimated relative transformation between respective poses of the pair, based on the identified data sets of the pair, determining an initial maximum likelihood configuration of poses of all of the range finders based on the estimated relative transformations of each pair and iteratively determining sets of point correspondences of the identified data sets and if a distance of the points in the pair is below a threshold, the threshold being redefined decreasingly for each iteration.

Abstract: A compound of formula (1), (1?), (1?) or (1??) or a pharmaceutically acceptable salt thereof, for use in the treatment of diseases or conditions for which a bromodomain inhibitor is indicated.

Abstract: An exemplary system, method and computer-accessible medium for determining a plurality of tissue parameters of a tissue(s), can include, for example, receiving information related to a plurality of rotational invariants contained within a diffusion magnetic resonance (dMR) image(s) of the tissue(s), and generating the tissue parameters using a set of rotational invariants related to the plurality of tissue parameters using such information. The tissue parameters can be generated by factorizing a response of an individual fiber segment of the tissue(s) based on the set of rotational invariants. The response of the individual fiber segments can be factorized from an orientational distribution function (“ODF”). The individual fiber segments can be factorized using a scalar tensor factorization(s) of the rotational invariants. The set of rotational invariants can be of a rotation group SO(3).

Abstract: A fluid pump for pumping a fluid from an inlet toward an outlet comprises a pump body, a pump diaphragm, and a valve seat. The pump body has a first opening and a second opening. The pump diaphragm is attached to the pump body and forms a pump chamber between the pump body and the pump diaphragm. The pump chamber is fluidly connected to the inlet by the first opening and to the outlet by the second opening. The valve seat is disposed inside the pump chamber and around the second opening. The valve seat protrudes with an undeformed height from the second opening into the pump chamber in a direction toward the pump diaphragm. The valve seat has an elastic body and a gasket with a sealing surface. The pump diaphragm is deflectable and is adapted to open and close a fluidic pathway of the outlet by moving into and out of contact with the valve seat.

Abstract: A method for accelerating magnetic resonance imaging is proposed. In 3D MRI, the method utilizes two sub-echo-trains in each repetition time for the simultaneous acquisition of two contrasts. The first sub-echo-train is a turbo spin echo train and the second sub-echo-train is a gradient echo train. The method acquires two different contrasts simultaneously in a single acquisition, for example one water image plus one fat image, or one turbo spin echo image plus one susceptibility weighted image.

Abstract: A method for producing a micro-LED matrix by (A) depositing an LED layer structure onto a working substrate; (B) singulating a plurality of LED structures from the LED layer structure on the working substrate; (C) applying a first contact-making structure to a carrier substrate; and (D) transferring the plurality of LED structures from the working substrate to the carrier substrate by bonding and laser lift-off. An at least two-layered carrier substrate is used, including a carrier layer and a first flexible polymer layer, in step C the first contact-making structure is applied indirectly or directly to a side of the first polymer layer which faces away from the carrier layer, and in an additional method step D-0 between method steps C and D, a second flexible polymer layer is formed at least between the singulated LED structures. A micro-LED matrix and use are also provided.

Abstract: The invention relates to the use of aryliodonium and/or arylsulfonium salts of the tetrakis(perfluoro-t-butyloxy)aluminate anion of the following formula (I): as cationic initiators cleavable by light and/or free radicals for polymerizing cationically polymerizable monomers.

Abstract: The invention relates to a device (1) and a method for the optical stimulation of an optically activatable biological sample (3), comprising at least one light source (13; 13?, 13?), which emits light of at least one predetermined wavelength that impinges directly or indirectly on the sample (3). The invention is characterized in that: the at least one light source (13; 13?, 13?) is thermally coupled to a hollow channel section (4); the hollow channel section (4) is part of a fluid circuit through which fluid flows; a temperature-control unit (12) and a conveying pump are arranged along the fluid circuit; and the hollow channel section (4) has at least one limiting wall (5) onto which the optically activatable biological samples (3) are thermally coupled in a direct or indirect manner.

Abstract: The invention relates to a method of diagnosing breast cancer and to the use of biomarkers for the detection and diagnosis of breast cancer.

Abstract: A carrier structure (2) of an arrangement (1) for modifying a main magnetic field generated in a magnetic resonance tomograph from multiple carrier elements (3, 37). A conductor arrangement (4) is respectively arranged on each carrier element (3, 37). The conductor arrangements (4) respectively include a primary conductor arrangement (6) for generating a primary magnetic field that modifies the main magnetic field and a secondary conductor arrangement (7) for shielding the primary magnetic field. A method for producing a modularly constructible arrangement (1) is provided, which can be used for example for spatial encoding.

Abstract: The present invention relates to a method for producing renal cells, comprising overexpressing Hnf1b and Pax8, and optionally Hnf4a and/or Emx2 in differentiated cells.

Abstract: The present invention concerns a construct for epigenomic modification of genes that includes the following components: a) a Krüppel-associated box zinc finger protein or homologous, b) a DNA region capable of binding to the target gene or homologous, c) a human DNA methyltransferase DNMT3A or homologous and d) a murine DNA methyltransferase Dnmt3L or homologous whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.

Abstract: The present invention concerns a construct for epigenomic modification of genes comprising the following components: a) a Krüppel-associated box zinc finger protein or homologous, b) a DNA region capable of binding to the target gene or homologous, c) a human DNA methyltransferase DNMT3A or homologous and d) a murine DNA methyltransferase Dnmt3L or homologous whereby components a), b), c) and d) are linked to each other either directly or via at least one linker. The construct is a designer epigenome modifier which can be used to silence genes coding for a protein in leukocytes which avoids the internalization of HI viruses in immune cells.

Abstract: The field of the invention relates to a method for the production of a recombinant protein in a plant-based system comprising the steps of providing a plant-based system comprising a modulation for a plant endogenous prolyl-4-hydroxylase gene, delivering a gene encoding the recombinant protein into the plant-based system, and cultivating the plant-based system for the expression of the gene encoding the recombinant protein. The field of the invention further relates to a recombinant protein, which has been produced in a plant-based system. A plant-based system and use of the recombinant protein are also provided.

Abstract: A charge balancing circuit is adapted to be connected to an electrode and to a stimulation source. The charge balancing circuit has an electrode terminal for receiving an electrode voltage, an amplifier coupled to the electrode terminal and adapted to amplify and invert the electrode voltage for generating an intermediate voltage and a compensation stage. The compensation stage is adapted to generate an output current if the electrode voltage lies outside a specified safety range and to generate the output current depending on the intermediate voltage. The compensation stage is further adapted to supply the output current to the electrode terminal for driving the electrode voltage towards and/or into the safety range.

Abstract: The present invention relates to materials and methods suitable for determining the presence or amount of Botulinum toxin (BoNT) in a test sample by means of a luminescence assay in which the substrate peptide is composed of: an amino acid sequence susceptible to proteolytic cleavage by BoNT, an amino acid sequence corresponding to a reporter domain encoding a fluorescent or bioluminescent polypeptide, and a tag suitable for attaching the substrate peptide to a suitable support, preferably by covalent bond.

Abstract: The present invention discloses new medical uses of phosphodiesterase 4 (PDE 4) inhibitors for treating dyslipoproteinaemia and of diseases when respectively correlated or associated with dyslipoproteinaemia or lipoprotein imbalance, in particular abnormally high low density lipoprotein (LDL) in blood or serum, such as endothelial dysfunction, cardiovascular diseases, in particular arteriosclerosis, myocardial infarction, stroke, peripheral artery disease, and vascular stenosis or restenosis, independent and distinct from inflammatory diseases or conditions such as inflammatory-associated cardiovascular pathology and cardiac hypertrophy. Accordingly the present invention allows reducing cardiovascular risks in new clinical settings, especially in circumstances of abnormal high LDL levels and especially LDL-cholesterol and LDL-triglyceride levels.